Standout Papers
- Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009)
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus (2002)
- Guidelines for Treatment of Candidiasis (2004)
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia (1994)
- Resistance of Candida species to fluconazole (1995)
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections (1997)
- Practice Guidelines for the Treatment of Candidiasis (2000)
- A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients (2003)
- Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials (2012)
- Social Behaviour, Its Elementary Forms (1962)
- Antibiotic development — economic, regulatory and societal challenges (2019)
- Critical analysis of antibacterial agents in clinical development (2020)
- Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. (2022)
Immediate Impact
5 by Nobel laureates 7 from Science/Nature 165 standout
Citing Papers
Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance
2024 Standout
Works of John Rex being referenced
Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020
2021
White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John Rex | 18457 | 14758 | 2237 | 2307 | 288 | 27.2k | |
| John R. Wingard | 13384 | 13803 | 1597 | 2043 | 430 | 32.6k | |
| John E. Edwards | 16107 | 12370 | 2764 | 4365 | 218 | 26.2k | |
| Po‐Ren Hsueh | 14841 | 12286 | 3170 | 5321 | 960 | 36.9k | |
| Eleftherios Mylonakis | 9024 | 7445 | 1277 | 5235 | 422 | 21.5k | |
| Jeremy Farrar | 21018 | 9371 | 573 | 4492 | 450 | 43.8k | |
| Steven M. Holland | 11686 | 14878 | 896 | 7401 | 710 | 46.1k | |
| Matthew E. Falagas | 7924 | 15007 | 7753 | 5643 | 589 | 46.4k | |
| Didier Pittet | 21072 | 9694 | 1228 | 2799 | 562 | 41.8k | |
| Arturo Casadevall | 26052 | 27624 | 1572 | 12174 | 872 | 51.6k | |
| Richard D. Moore | 15983 | 12088 | 1987 | 1243 | 618 | 29.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...